/MDWD
MDWD Stock - MediWound Ltd.
Healthcare|BiotechnologyNASDAQ
$18.77-0.37%
$0.07 (-0.37%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+91.8%upside
Target: $36.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MDWD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$18.58 – $18.96
TARGET (TP)$36.00
STOP LOSS$17.27
RISK/REWARD1:11.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.07
52W High$22.50
52W Low$14.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $20.22M | $18.69M | $26.50M | $23.76M | $21.76M |
| Gross Profit | $1.78M | $2.95M | $12.32M | $8.14M | $7.01M |
| Gross Margin | 8.8% | 15.8% | 46.5% | 34.2% | 32.2% |
| Operating Income | $-19,383,000 | $-15,501,000 | $-7,661,000 | $-11,221,000 | $-8,840,000 |
| Net Income | $-30,224,000 | $-6,716,000 | $-19,599,000 | $-13,551,000 | $-9,196,000 |
| Net Margin | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% |
| EPS | $-3.03 | $-0.75 | $-3.93 | $-3.48 | $-2.38 |
Company Overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$24
Average Target
↑ 29.6% Upside
Now
$7
Low
$24
Average
$39
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $34 |
| May 2nd 2025 | Alliance Global Partners | Initiation | Buy | $25 |
| February 28th 2025 | Craig Hallum | Initiation | Buy | $39 |
| July 16th 2024 | Maxim Group | Reiterated | Buy | $30← $25 |
| December 22nd 2022 | Maxim Group | Initiation | Buy | $11 |
| July 18th 2022 | Oppenheimer | Resumed | Outperform | $7 |
Earnings History & Surprises
MDWDBeat Rate
44%
Last 18 quarters
Avg Surprise
-30.7%
EPS vs Estimate
Beats / Misses
8/9
1 met exactly
Latest EPS
$-0.24
Q4 2025
EPS Surprise History
Q1 24
+17.4%
$-0.19vs$-0.23
Q2 24
+2.5%
$-0.39vs$-0.40
Q3 24
-61.9%
$-0.68vs$-0.42
Q4 24
-122.7%
$-0.98vs$-0.44
Q1 25
+39.0%
$-0.36vs$-0.59
Q2 25
+89.2%
$-0.07vs$-0.65
Q3 25
-123.6%
$-1.23vs$-0.55
Q4 25
+70.4%
$-0.24vs$-0.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.59 | — | — | — |
Q4 2025 | Nov 20, 2025 | $-0.81 | $-0.24 | +70.4% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.55 | $-1.23 | -123.6% | ✗ MISS |
Q2 2025 | May 21, 2025 | $-0.65 | $-0.07 | +89.2% | ✓ BEAT |
Q1 2025 | Mar 19, 2025 | $-0.59 | $-0.36 | +39.0% | ✓ BEAT |
Q4 2024 | Nov 26, 2024 | $-0.44 | $-0.98 | -122.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.42 | $-0.68 | -61.9% | ✗ MISS |
Q2 2024 | May 29, 2024 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q4 2023 | Nov 21, 2023 | $-0.45 | $-0.24 | +46.7% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $-0.40 | $0.10 | +125.0% | ✓ BEAT |
Q2 2023 | May 30, 2023 | $-0.31 | $-0.44 | -41.9% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.19 | $-1.18 | -521.1% | ✗ MISS |
Q4 2022 | Nov 15, 2022 | $-0.70 | $-0.91 | -30.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.70 | $-0.91 | -30.0% | ✗ MISS |
Q2 2022 | May 17, 2022 | $-0.77 | $-0.84 | -9.1% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-1.12 | $-1.05 | +6.3% | ✓ BEAT |
Q4 2021 | Nov 16, 2021 | $-0.84 | $-0.84 | 0.0% | = MET |
Q3 2021 | Aug 10, 2021 | $-0.77 | $-0.84 | -9.1% | ✗ MISS |
Latest News
MediWound Announces Peer-Reviewed Publication Of New Prospective Clinical Data Showing NexoBrid Substantially Reduces Embedded Particles Associated With Traumatic Tattoos Following Abrasion And Blast Injuries
📈 PositiveBenzinga•Dec 10, 2025, 12:13 PM
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $36
📈 PositiveBenzinga•Nov 21, 2025, 11:16 AM
MediWound Q3 EPS $(0.24) Beats $(0.81) Estimate, Sales $5.429M Miss $6.646M Estimate
➖ NeutralBenzinga•Nov 20, 2025, 12:02 PM
MediWound announces $30 million registered direct offering; shares down over 7%
📉 NegativeSeeking Alpha•Sep 29, 2025, 12:57 PM
MediWound Secures TGA Approval For NexoBrid In Australia For Adult And Pediatric Patients With Thermal Burns
📈 PositiveBenzinga•Sep 25, 2025, 11:56 AM
MediWound Revenue Jumps 43% in Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 06:22 PM
Frequently Asked Questions about MDWD
What is MDWD's current stock price?
MediWound Ltd. (MDWD) is currently trading at $18.77 per share. The stock has moved -0.37% today.
What is the analyst price target for MDWD?
The average analyst price target for MDWD is $36.00, based on 1 analyst.
What sector is MediWound Ltd. in?
MediWound Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MDWD's market cap?
MediWound Ltd. has a market capitalization of $0.20 billion, making it a small-cap company.
Does MDWD pay dividends?
No, MediWound Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
NTHI
Neonc Technologies Holdings, Inc.
$7.01
Mkt Cap: $0.1B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
RNAC
Cartesian Therapeutics, Inc.
$7.22
Mkt Cap: $0.2B
SLS
SELLAS Life Sciences Group, Inc.
$2.36
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to MDWD for comparison